Nancy Dumais » Autres publications

Dumais N., Paré M.E., Mercier S., Bounou S., Marriot S.J., Barbeau B. et Tremblay M.J. 2003. T-cell receptor/CD28 engagement when combined with prostaglandin E2 treatment leads to potent activation of Human T-cell Leukemia Virus type 1. J. Virol. 77(20):11170-9.

Dumais N., Patrick A., Moss R.B., Davis H.L. et Rosenthal K.L. 2002. Intranasal immunization with type-1 gp120-depleted HIV-1 immunogen plus CpG ODN induces immune responses in the genital tract and protection against intravaginal challenge. J. Inf. Dis. 186(8):1098-105.

Dumais N., Patrik A., Moss R.B., Davis H.L. and Rosenthal K.L., 2002. Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge. J. Inf. Dis. 186 :1098-1105.

Dumais N., Bounou S., Olivier M. and Tremblay M.J. 2002. Prostaglandin E2-mediated activation of HIV-1 long terminal repeat transcription in human T cells necessitates CCAAT/enhancer binding protein (C/EBP) binding sites in addition to cooperative interactions between C/EBPbeta and cyclic adenosine 5'-monophosphate response element binding protein. J. Immunol. 168:274-282.

Bounou S., Dumais N. and Tremblay M.J. 2001.  Attachment of HIV-1 particles bearing host-encoded B7-2 proteins leads to NF-kB and NFAT-dependent activation of HIV-1 LTR transcription.  J. Biol. Chem.  276:6359-6369.

Savard M., Bélanger C., Tremblay M.J., Dumais N., Flamand L., Borgeat P. and Gosselin J. 2000.  EBV suppresses prostaglandin E2 biosynthesis in human.  J. Immunol. 164:6467-6473.

Dumais N., Barbeau B., Olivier M. and Tremblay M.J. 1998. Prostaglandin E2 up regulates HIV-1 LTR-driven gene activity in T cells via NF-kB-dependent and -independent signalling pathways.  J. Biol. Chem. 273:27306-27314.

Barbeau B., Bernier R., Dumais N., Briand G., Olivier M., Faure R., Posner B.I. and Tremblay MJ. 1997.  Activation of HIV-1 long terminal repeat transcription and virus replication via NF-kB-dependent and -independent pathways by potent phosphotyrosine phosphatase inhibitors, the peroxovanadium compounds.  J. Biol. Chem. 272:12968-12977.

Nancy Dumais » Autres publications